anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Vaso-active substances obtained from gingko biloba leaves. F3A. Used for treating peripheral and cerebral arterial circulation disorders in the aged and are extracted from fresh or dried green leaves of Gingko biloba L. syn. Salisburia adiantifolia Smith with an organic solvent (lower alcohol or ketone) miscible with water and containing water at pref. 60-80 degrees C. This extract is itself extracted with a lipophilic solvent (lower halogenated aliphatic hydrocarbon) immiscible with water at 15-50 degrees C opt. followed by evaporation of the aqueous organic phase under reduced pressure. The extract contains quercitine, isoquercitine, luteoline and kamferol-3-rhamnoside glycosides and sitosterine and as the extractions take place under very moderate conditions, the active substances are obtained in their original form. The aqueous organic phase extract can be used without purification for oral administration but not for injections, when it must be treated with (NH4)2SO4, extracted with organic solvent partially soluble in H2O / (C2H5)2CO or C2H5COCH3/, evapd., extracted with low aliphatic alcohol (pref. C2H5OH), residue dried under reduced pressure, powder dissolved in water, pH adjusted to 7.5 and this soln. diluted 9 times with 4% soln. of sorbitol in H2O.
PURPOSE: A surface-modifying pigment for cosmetic product is provided to ensure softness and affinity to the skin. CONSTITUTION: A surface-modifying pigment is obtained by surface modification of a pigment with triethoxyalkylsilane of the chemical formula 1 and amodimethicone of the chemical formula 2. The chemical formula 1 is denoted by CH3(CH2)n Si(OCH2CH3)3. In the formula 1, n is 7 to 17. In the chemical formula 2, R is OH or CH3, and X is propyl group, isopropyl group or isobutyl group. The pigment is selected from talc, sericite, mica, titanium dioxide, kaolin, silica and alumina.
First phase of the home user trial. 19 users, 12 who were part of a couple and 7 who were single.
Teratogenic Effects

Pregnancy Category C. There are no adequate and well-controlled trials with VENTOLIN HFA or albuterol sulfate in pregnant women. During worldwide marketing experience, various congenital anomalies, including cleft palate and limb defects, have been reported in the offspring of patients being treated with albuterol. Some of the mothers were taking multiple medications during their pregnancies. No consistent pattern of defects can be discerned, and a relationship between albuterol use and congenital anomalies has not been established. Animal reproduction studies in mice and rabbits revealed evidence of teratogenicity. VENTOLIN HFA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Women should be advised to contact their physicians if they become pregnant while taking VENTOLIN HFA.

In a mouse reproduction study, subcutaneously administered albuterol sulfate produced cleft palate formation in 5 of 111 (4.5%) fetuses at exposures less than the maximum recommended human daily inhalation dose (MRHDID) for adults on a mg/m 2 basis and in 10 of 108 (9.3%) fetuses at approximately 8 times the MRHDID. Similar effects were not observed at approximately one eleventh of the MRHDID. Cleft palate also occurred in 22 of 72 (30.5%) fetuses from females treated subcutaneously with isoproterenol (positive control). 

In a rabbit reproduction study, orally administered albuterol sulfate produced cranioschisis in 7 of 19 fetuses (37%) at approximately 680 times the MRHDID.

In another rabbit study, an albuterol sulfate/HFA-134a formulation administered by inhalation produced enlargement of the frontal portion of the fetal fontanelles at approximately one third of the MRHDID.

Nonteratogenic Effects

A study in which pregnant rats were dosed with radiolabeled albuterol sulfate demonstrated that drug-related material is transferred from the maternal circulation to the fetus.
BACKGROUND: Providing healthcare for older adults with multiple chronic conditions (MCC) is challenging. Polypharmacy and complex treatment plans can lead to high treatment burden and risk for adverse events. For clinicians, managing the complexities of patients with MCC leaves little room to identify what matters and align care options with patients' health priorities. New care approaches are needed to navigate these challenges. In this clinical trial, we evaluate implementation and effectiveness outcomes of an innovative, structured, patient-centered care approach (Patient Priorities Care; PPC) for reducing treatment burden and aligning health care decisions with the health priorities of older adults with MCC.
METHODS: This is a multisite, assessor-blind, two-arm, parallel hybrid type 1 randomized controlled trial. We are enrolling 396 older (65+) Veterans with MCC who receive primary care at the Veterans Affairs Medical Center. Veterans are randomly assigned to either PPC or usual care. In the PPC arm, Veterans have a brief telephone call with a study facilitator to identify their personal health priorities. Then, primary care providers use this information to align healthcare with Veteran priorities during their established clinic appointments. Data are collected at baseline and 4-month follow up to assess for changes in treatment burden and use of home and community services. Formative and summative evaluations are also collected to assess for implementation outcomes according to Proctor's implementation framework.
CONCLUSIONS: This work has the potential to significantly improve the standard of care by personalizing healthcare and helping patients achieve what is most important to them.
The second strategy is based on the partograph developped by Neal and Lowe. An active management of labour is started when crossing the dystocia line or when there are no cervical modifications after 4 hours beyond 5 cm of cervical dilation. In this case, active management of labour is started with introduction of oxytocin, artificial rupture of membranes and supportive therapy.
Gemcitabine is given at the standard dose of 1250 mg/m2 i.v. in 500ml NaCl 0.9% (sodium chloride) as an infusion over 30 minutes, on an ambulatory basis.
Diagnosing and treating liver fibrosis is a challenging yet crucial endeavor due to its complex pathogenesis and risk of deteriorating into cirrhosis, liver failure, and even hepatic cancer. Herein, a silica cross-linked micelles (SCLMs) based nano-system is developed for both diagnosing and treating liver fibrosis. The SCLMs are first modified with peptide CTCE9908 (CT-SCLMs) and can actively target CXCR4, which is overexpressed in activated hepatic stellate cells (HSCs). To enable diagnosis, an ONOO--responded near-infrared fluorescent probe NOF2 is loaded into the CT-SCLMs. This nano-system can target the aHSCs and diagnose the liver fibrosis particularly in CCl4-induced liver damage, by monitoring the reactive nitrogen species. Furthermore, a step is taken toward treatment by co-encapsulating two anti-fibrosis drugs, silibinin and sorafenib, within the CT-SCLMs. This combined approach results in a significant alleviation of liver injury. Symptoms associated with liver fibrosis, such as deposition of collagen, expression of hydroxyproline, and raised serological indicators show notable improvement. In summary, the CXCR4-targeted nano-system can serve as a promising theragnostic system of early warning and diagnosis for liver fibrosis, offering hope against progression of this serious liver condition.
Cervical human papillomavirus (HPV) infection is believed to increase the risks of pregnancy failure and abortion, however, whether the uterine cavity HPV infection reduces pregnancy rate or increases miscarriage rate remains unclarified in infertile women undergoing assisted reproductive technology (ART) treatment. Therefore, we aimed to assess ART outcomes in the presence of intrauterine HPV. This was a hospital-based multicenter (five reproductive medicine centers) matched cohort study. This study involved 4153 infertile women undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection treatment in five reproductive medicine centers between October 2018 and 2020. The spent embryo transfer media sample with endometrium tissue were collected and performed with flow-through hybridization and gene chips to detect HPV DNA. According to basic characteristics, HPV-positive and negative patients were matched in a ratio of 1:4 by age, body mass index transfer timing, transfer type, and number of embryos transferred. The primary outcome was pregnancy and clinical miscarriage rates in the transfer cycle underwent HPV detection. 92 HPV-positive and 368 HPV-negative patients were screened and analyzed statistically. Univariate analysis showed uterine cavity HPV infection resulted in lower rates of ongoing pregnancy (31.5% vs. 44.6%; p = 0.023), implantation (32.3% vs. 43.1%; p = 0.026), biochemical pregnancy (47.8% vs. 62.5%; p = 0.010), and clinical pregnancy (40.2% vs. 54.3%; p = 0.015) compared with HPV negative group. The infertile female with positive HPV also had a slightly higher frequency of biochemical miscarriage (15.9% vs. 13.0%; p = 0.610) and clinical miscarriage (24.3% vs. 15.5%; p = 0.188). These findings suggest that HPV infection in the uterine cavity is a high risk for ART failure. HPV screening is recommended before ART treatment, which may be benefit to improving pregnancy outcome.
The present invention relates to a method for detecting the activity of royal jelly and freeze-dried powder. The method comprises the following steps: (1). royal jelly feed is prepared, (2). one-day larvae with constant size and growth are selected from a disease-free swarm; (3). the feed is evenly spread into a culture device, the humidity is maintained to be more than 90%, the feed is put in a culture box, and the temperature is controlled to a range of 33 to 35 DEG C; (4). 30 one-day larvae are put in the culture device, put in a column temperature box and cultured; (5). feed is changed every day, and the weight of the larvae is weighed; (6). on the 7th day, each of the larvae is weighed one by one, and the results are counted. The present invention has the advantages of simple and practical operation and convenient implementation, and can comprehensively and accurately reflect the nutrient conditions of the royal jelly or the freeze-dried powder. The present invention is more scientific than the detection through traditional devices; the present invention opens up a new path for detecting the activity of royal jelly and freeze-dried powder and provides a scientific effective method for controlling the quality of royal jelly and freeze-dried powder.
There is limited clinical experience with VIMPAT overdose in humans. The highest reported accidental overdose of VIMPAT during clinical development was 1200 mg/day which was non-fatal. The types of adverse events experienced by patients exposed to supratherapeutic doses during the trials were not clinically different from those of patients administered recommended doses of VIMPAT.

There has been a single case of intentional overdose by a patient who self-administered 12 grams VIMPAT along with large doses of zonisamide, topiramate, and gabapentin. The patient presented in a coma and was hospitalized. An EEG revealed epileptic waveforms. The patient recovered 2 days later.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention describes new bicyclic derivatives of imidazole of the general formula (I)   where X, n, A 1 ,A 2 ,A 3 ,A 4 ,X 2  are given in p. 1 of the invention claim. Compounds show antagonistic properties for acceptor to angiotensin-II and inhibitory activity with respect to angiotensin-II. Invention describes also a pharmaceutical composition based on the compound of the formula (I), an intermediate compound and a method of its synthesis. EFFECT: improved method of synthesis, valuable pharmacological properties. 9 cl, 31 ex
BACKGROUND: The aim of this study was to assess the outcomes of the combination technique of strip free gingival grafts (SFGG) and xenogeneic collagen matrix (XCM) in augmenting the width of keratinized mucosa (KMW) around dental implants, and compare its efficacy with the historical control group (FGG).
METHODS: Thirteen patients with at least one site with KMW ≤ 2 mm after implant surgery were included and received SFGG in combination with XCM. Another thirteen patients with the same inclusion and exclusion criteria from the previous trial received FGG alone. The same outcomes as the previous trial were evaluated. KMW, thickness of keratinized mucosa (KMT), gingival index (GI) and probing depth (PD) were measured at baseline, 2 and 6 months. Postoperative pain, patient satisfaction and aesthetic outcomes were also assessed.
RESULTS: At 6 months after surgery, the combination technique could attain 3.3 ± 1.6 mm of KMW. No significant change could be detected in GI or PD at 6 months compared to those at 2 months (p > 0.05). The postoperative pain and patient satisfaction in VAS were 2.6 ± 1.2 and 9.5 ± 1.2. The total score of aesthetic outcomes was 3.8 ± 1.2. In the historical FGG group, 4.6 ± 1.6 mm of KMW was reported at 6 months, and the total score of aesthetic outcomes was higher than the combination technique (4.8 ± 0.7 vs. 3.8 ± 1.2, p < 0.05).
CONCLUSIONS: The combination technique of SFGG and XCM could increase KMW and maintain peri-implant health. However, this combination technique was associated with inferior augmentation and aesthetic outcomes compared with FGG alone.
TRIAL REGISTRATION: This clinical trial was registered in the Chinese Clinical Trial Registry with registration number ChiCTR2200057670 on 15/03/2022.
Subjects received radiotherapy (SBRT+LDRT). Sintilimab combined with standard platinum-containing double-drug chemotherapy was performed within 1 week after the end of radiotherapy.
This study identified determinants of malnutrition among school children in West Bengal, India. A total of 896 children aged between 4 and 13 years in eight districts were evaluated. BMI, weight, and height-for-age z-scores were used to categorize the stages of malnutrition. The study results revealed that the average height of the boys and girls was as per the standards set by the National Council of Health Sciences. Body mass index of the children ranged between 14.4 and 21.42 kg/m2, and stunting was 56.77%. Age and stunting were positively correlated in 5- to 10-year-old children. The most common deficiency was of fluoride.
Microglia, brain-resident macrophages, can acquire distinct functional phenotypes, which are supported by differential reprogramming of cell metabolism. These adaptations include remodeling in glycolytic and mitochondrial metabolic fluxes, potentially altering energy substrate availability at the tissue level. This phenomenon may be highly relevant in the brain, where metabolism must be precisely regulated to maintain appropriate neuronal excitability and synaptic transmission. Direct evidence that microglia can impact on neuronal energy metabolism has been widely lacking, however. Combining molecular profiling, electrophysiology, oxygen microsensor recordings and mathematical modeling, we investigated microglia-mediated disturbances in brain energetics during neuroinflammation. Our results suggest that proinflammatory microglia showing enhanced nitric oxide release and decreased CX3CR1 expression transiently increase the tissue lactate/glucose ratio that depends on transcriptional reprogramming in microglia, not in neurons. In this condition, neuronal network activity such as gamma oscillations (30-70 Hz) can be fueled by increased ATP production in mitochondria, which is reflected by elevated oxygen consumption. During dysregulated inflammation, high energy demand and low glucose availability can be boundary conditions for neuronal metabolic fitness as revealed by kinetic modeling of single neuron energetics. Collectively, these findings indicate that metabolic flexibility protects neuronal network function against alterations in local substrate availability during moderate neuroinflammation.
Refrigerate PAVBLU at 2°C to 8ºC (36°F to 46ºF). PAVBLU may be kept at room temperature (up to 30° C (86° F)) for a single-period of 3 days. Do not freeze. Do not use beyond the date stamped on the carton and container label. Store in the original carton until time of use to protect from light. Do not open sealed blister tray until time of use.
PROBLEM TO BE SOLVED: To obtain a cosmetic base comprising polyoxyethylenated polypropylene glycol, not generating a stench when produced and after stored for a long period, and useful as an emulsifier, a humectant, etc. SOLUTION: This cosmetic base comprises polyoxyethylenated polypropylene glycol having a propenyl ether group content of <=0.001 milliequivalent/g. The component A is preferably the ethylene oxide adduct of polypropylene glycol obtained by addition-reacting propylene oxide to a glycol compound in the presence of 0.03-3 wt.% of potassium-based and/or cesium-based catalyst (for example, potassium hydroxide or cesium hydroxide) at a temperature of 60-90 deg.C. After subjected to the removal of the catalysts and to the neutralization of the product, the obtained component A is stored. The number-average mol.wt. of the polypropylene glycol portion in the cosmetic base is preferably 1,500-4,500.
In one embodiment, a WCD is described. The WCD includes a support structure configured to be worn by a patient and a processor coupled to the support structure. The WCD also includes an energy storage module configured to store an electrical charge and in communication with the processor. The WCD also includes a discharge circuit coupled to the energy storage module, the discharge circuit in communication with the processor and configured to discharge the stored electrical charge through a body of the patient. The processor is configured to detect an event at the WCD, classify the detected event, and determine an alarm onset time of the detected event based at least in part on the event classification. The processor is further configured to issue the alarm after the alarm onset time.
Patients will receive 2.5 mg of vaginal bromocriptine tablet twice a day for the intervention. This will be administered for 6 months.
Trained peer supporters will answer calls from potential participants and explain the nature and purpose of the project to them. Each participant will then receive a brief intervention over the telephone that will be delivered by a trained peer supporter using the Ask, Warn, Advise, Refer and Do-it-Again (AWARD) model. Participants will be asked to quit drugs immediately or progressively. In addition, they will be informed that they will receive instant messaging via WeChat or WhatsApp from peer supporters to assist them to adhere to their schedule of quitting drugs throughout the study period. For the first six months, participants will receive four independent 1-minute videos which focus on the health risks associated with abusing drugs and the benefits of quitting drugs without any schedule of the desirable health-related lifestyle throughout the study period.
BACKGROUND: The World Health Organization (WHO) recommends balanced energy and protein (BEP) supplementation be provided to all pregnant women living in undernourished populations, usually defined as having a prevalence > 20% of underweight women, to reduce the risk of stillbirths and small-for-gestational-age neonates. Few geographies meet this threshold, however, and a large proportion of undernourished women and those with inadequate gestational weight gain could miss benefiting from BEP. This study compares the effectiveness of individual targeting approaches for supplementation with micronutrient-fortified BEP vs. multiple micronutrient supplements (MMS) alone as control in pregnancy in improving birth outcomes.
METHODS: The TARGET-BEP study is a four-arm, cluster-randomized controlled trial conducted in rural northwestern Bangladesh. Eligible participants are married women aged 15-35 years old identified early in pregnancy using a community-wide, monthly, urine-test-based pregnancy detection system. Beginning at 12-14 weeks of gestation, women in the study area comprising 240 predefined sectors are randomly assigned to one of four intervention arms, with sector serving as the unit of randomization. The interventions involving daily supplementation through end of pregnancy are as follows: (1) MMS (control); (2) BEP; (3) targeted BEP for those with pre-pregnancy body mass index (BMI) < 18.5 kg/m2 and MMS for others; (4) targeted BEP for those with pre-pregnancy BMI < 18.5 kg/m2, MMS for others, and women with inadequate gestational weight gain switched from MMS to BEP until the end of pregnancy. Primary outcomes include birth weight, low birth weight (< 2500 g), and small for gestational age, defined using the 10th percentile of the INTERGROWTH-21st reference, for live-born infants measured within 72 h of birth. Project-hired local female staff visit pregnant women monthly to deliver the assigned supplements, monitor adherence biweekly, and assess weight regularly during pregnancy. Trained data collectors conduct pregnancy outcome assessment and measure newborn anthropometry in the facility or home depending on the place of birth.
DISCUSSION: This study will assess the effectiveness of targeted balanced energy and protein supplementation to improve birth outcomes among pregnant women in rural Bangladesh and similar settings.
TRIAL REGISTRATION: ClinicalTrials.gov NCT05576207. Registered on October 5th, 2022.
Study arm will consume a western diet eating as they normally would for 9 weeks. With low MEdDIet score.
Small-cell lung cancer (SCLC) is the most aggressive and lethal type of lung cancer, characterized by limited treatment options, early and frequent metastasis. However, the determinants of metastasis in SCLC are poorly defined. Here, we show that estrogen-related receptor gamma (ERRγ) is overexpressed in metastatic SCLC tumors, and is positively associated with SCLC progression. ERRγ functions as an essential activator of extracellular matrix (ECM) remodeling and cell adhesion, two critical steps in metastasis, by directly regulating the expression of major genes involved in these processes. Genetic and pharmacological inhibition of ERRγ markedly reduces collagen production, cell-matrix adhesion, microfilament production, and eventually blocks SCLC cell invasion and tumor metastasis. Notably, ERRγ antagonists significantly suppressed tumor growth and metastasis and restored SCLC vulnerability to chemotherapy in multiple cell-derived and patient-derived xenograft models. Taken together, these findings establish ERRγ as an attractive target for metastatic SCLC and provide a potential pharmacological strategy for treating this lethal disease.
The invention discloses a recombinant protein specifically combined with collagen, a coding gene and application thereof. The coding gene sequence of the recombinant protein specifically combined with collagen is shown in SEQ ID NO. 1-3. The recombinant protein comprises a collagen binding region and hepatocyte growth factor linked to the collagen binding region. The invention also discloses a coding gene of the recombinant protein and application thereof. The invention modifies the protein structure of hepatocyte growth factor HGF to enable the fusion expression of the protein structure to be capable of specifically binding with the collagen sequence, and endows the protein structure with the capability of specifically binding with the collagen; meanwhile, the recombinant protein specifically combined with the collagen has a good function of promoting migration and angiogenesis of endothelial cells, and can be combined with the collagen material with high efficiency to form a functional collagen material, so that the functional collagen material can inhibit fibrosis of injured lung, promote migration and angiogenesis of endothelial cells, improve morphological recovery of injured lung and finally promote repair of lung injury.